Comparative Pharmacology
Head-to-head clinical analysis: FENOLDOPAM MESYLATE versus RAUVAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENOLDOPAM MESYLATE versus RAUVAL.
FENOLDOPAM MESYLATE vs RAUVAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dopamine D1-like receptor agonist (D1 and D5) causing vasodilation in renal, mesenteric, coronary, and cerebral arteries; increases renal blood flow and natriuresis.
Rauval (rauwolfia serpentina alkaloids) depletes catecholamines and serotonin from peripheral sympathetic nerve endings and the brain by binding to and inhibiting vesicular monoamine transporters (VMAT), thus reducing sympathetic outflow. This leads to vasodilation, decreased peripheral vascular resistance, and reduced blood pressure.
0.1 to 0.3 mcg/kg/min IV continuous infusion, titrated every 15-20 minutes by 0.05-0.1 mcg/kg/min; max dose 1.6 mcg/kg/min.
1.5 mg orally once daily, increased to 3 mg per day if needed. Maximum dose 6 mg per day.
None Documented
None Documented
Terminal elimination half-life approximately 10 minutes (range 5–20 min) in healthy adults; clinically, continuous infusion is required to maintain therapeutic effect due to rapid clearance.
Terminal elimination half-life is 7-10 hours in normal renal function; prolonged to 14-20 hours in renal impairment, requiring dose adjustment.
Renal (80% as metabolites, 10% as unchanged drug); fecal/biliary minor (10%)
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 20-30%.
Category C
Category C
Antihypertensive
Antihypertensive